Prognostic Impact of HER2 Overexpression in Intraductal Papillary Neoplasm of the Bile Duct
- 25 August 2025
- journal article
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 32 (11) , 838-846
Abstract
Background: Overexpression of human epidermal growth factor receptor 2 (HER2) is a recognized prognostic marker and therapeutic target in oncology. However, its clinical significance in intraductal papillary neoplasm of the bile duct (IPNB) remains unclear. Methods: This retrospective study reviewed patients who underwent resection for IPNB between 1998 and 2011. HER2 overexpression was evaluated by immunohistochemistry and semi‐quantitatively categorized into four grades (score 0, 1+, 2+, 3+); the former two and the latter two grades defined HER2‐negative and HER2‐positive groups, respectively. Results: A total of 184 IPNB cases were analyzed, of which 12 patients (6.5%) were diagnosed with HER2‐positive disease. There were no significant differences between the groups in clinicopathologic characteristics such as tumor location, histologic type, or invasion depth, with the exception of superficial extension, which was significantly more frequent in the HER2‐positive group. The HER2‐positive group demonstrated significantly worse overall survival than the HER2‐negative group (25% vs. 49% at 5 years, p = 0.030). In multivariable analysis, HER2 positivity, age ≥ 70, percutaneous transhepatic biliary drainage, nodal metastasis, and positive margin status were identified as independent prognostic factors. Conclusion: HER2 overexpression is an independent biologic marker for unfavorable survival, though infrequent in IPNB.Keywords
Funding Information
- Japan Society for the Promotion of Science (24K11928)
This publication has 23 references indexed in Scilit:
- Reappraisal of carcinoma in situ residue at the bile duct margin: a single-center review of 681 patients with perihilar cholangiocarcinomaHPB, 2024
- Intraductal papillary neoplasms of the bile ducts: a comparative study of a rare disease in Europe and Nagoya, JapanHPB, 2024
- Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and future perspectivesEuropean Journal of Cancer, 2024
- Utility of modified pancreaticoduodenectomy (Hi-cut PD) for middle-third cholangiocarcinoma: an alternative to hepatopancreaticoduodenectomyHPB, 2023
- Is a specific T classification needed for extrahepatic intraductal papillary neoplasm of the bile duct (IPNB) type 2 associated with invasive carcinoma?Journal of Hepato-Biliary-Pancreatic Sciences, 2022
- A proposal of drain removal criteria in hepatobiliary resectionJournal of Hepato-Biliary-Pancreatic Sciences, 2022
- A clinicopathological reappraisal of intraductal papillary neoplasm of the bile duct (IPNB): a continuous spectrum with papillary cholangiocarcinoma in 181 curatively resected casesHPB, 2021
- Adjuvant S‐1 vs gemcitabine for node‐positive perihilar cholangiocarcinoma: A propensity score‐adjusted analysisJournal of Hepato-Biliary-Pancreatic Sciences, 2021
- Clinicopathological characteristics of intraductal papillary neoplasm of the bile duct: a Japan‐Korea collaborative studyJournal of Hepato-Biliary-Pancreatic Sciences, 2020
- Prognostic delineation of papillary cholangiocarcinoma based on the invasive proportion: A single-institution study with 184 patientsSurgery, 2014